First-Line Immune Checkpoint Inhibitors for Poor Risk Metastatic RCC

Opinion
Video

Key opinion leaders in renal cell carcinoma provide a comprehensive overview of first-line immune checkpoint inhibitor combination regimens for patients with intermediate-to-poor risk metastatic renal cell carcinoma.

Current Time 0:00
Duration 7:38
Loaded: 0%
Stream Type LIVE
Remaining Time 7:38
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Recent Videos
    First-Line ICI-Based Combinations for mRCC With Sarcomatoid Features
    First-Line ICI-Based Combinations for mRCC With Sarcomatoid Features
    Patient Case: A 58-year-old Man With Hematuria and Abdominal Pain
    Patient Case: A 58-year-old Man With Hematuria and Abdominal Pain
    Third-Line Therapy for Patients with ccRCC
    Third-Line Therapy for Patients with ccRCC
    Indolent Metastatic ccRCC Disease Progression and Guideline Updates
    Indolent Metastatic ccRCC Disease Progression and Guideline Updates
    Optimizing ICI and TKI Combinations + Dose Reductions
    Optimizing ICI and TKI Combinations + Dose Reductions
    First-Line Immune Checkpoint Inhibitor for Favorable-Risk Metastatic Renal Cell Carcinoma
    First-Line Immune Checkpoint Inhibitor for Favorable-Risk Metastatic Renal Cell Carcinoma
    Patient Case: A 61-Year-Old Patient with Indolent Metastatic ccRCC
    Patient Case: A 61-Year-Old Patient with Indolent Metastatic ccRCC
    Patient Case: Workup and Imaging in RCC
    Patient Case: Workup and Imaging in RCC
    Monitoring Response in Immune Checkpoint Inhibitor-Based RCC Therapy
    Monitoring Response in Immune Checkpoint Inhibitor-Based RCC Therapy
    Cosmic-313 and Alternate Lines of Therapy for Poor Risk Metastatic RCC
    Cosmic-313 and Alternate Lines of Therapy for Poor Risk Metastatic RCC
    Related Content